Cancer Radiotherapie最新文献

{"title":"Observation of the efficacy and safety of concurrent intensity-modulated radiation with 5-fluorouracil and oxaliplatin for locally advanced nasopharyngeal carcinoma","authors":"Li Yanbing,&nbsp;Cai Lingyu,&nbsp;Zuo Hongbo,&nbsp;Li Zijun","doi":"10.1016/j.canrad.2025.104668","DOIUrl":"10.1016/j.canrad.2025.104668","url":null,"abstract":"<div><h3>Purpose</h3><div>The purpose of this study was to investigate the clinical efficacy and safety of concurrent intensity-modulated radiotherapy in combination with 5-fluorouracil and oxaliplatin for patients diagnosed with locally advanced nasopharyngeal carcinoma.</div></div><div><h3>Material and methods</h3><div>A total 66 patients with a newly diagnosed and previously treated locally advanced nasopharyngeal carcinoma were enrolled in this study. The patients were divided into two groups: the control group receiving intensity-modulated radiotherapy with 5-fluorouracil and cisplatin (<em>n</em> <!-->=<!--> <!-->33) and the observation group receiving intensity-modulated radiotherapy with 5-fluorouracil and oxaliplatin (<em>n</em> <!-->=<!--> <!-->33). Short-term efficacy, 6-month survival rate, recurrence rate, and distant metastasis rate of tumours were compared between the two groups. Furthermore, the incidence of treatment-related adverse reactions including nausea and vomiting, thrombocytopenia, hepatorenal syndrome, peripheral neuritis, and oral mucosa reaction was recorded.</div></div><div><h3>Results</h3><div>The overall efficacy rate of short-term treatment in the observation group was 96.97 %, compared to 93.94 % in the control group, indicating no statistically significant difference (<em>p</em> <!-->&gt;<!--> <!-->0.05). There were no significant differences observed between the two groups in terms of 6-month survival rate, recurrence rate, and distant metastasis rate (<em>p</em> <!-->&gt;<!--> <!-->0.05). The incidence of adverse reactions during treatment was 21.21 % in the observation group, which was significantly lower than that of 45.45 % in the control group (<em>p</em> <!-->&lt;<!--> <!-->0.05).</div></div><div><h3>Conclusion</h3><div>Concurrent intensity-modulated radiation therapy with 5-fluorouracil and oxaliplatin may achieve similar short-term outcomes as the standard regimen of 5-fluorouracil and cisplatin in the treatment of locally advanced nasopharyngeal carcinoma, with the added benefit of reduced toxicity.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 4","pages":"Article 104668"},"PeriodicalIF":1.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144571740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of 30-day mortality after palliative radiotherapy of 8 Gy in a single fraction as a quality criteria of patient management in a university hospital","authors":"Kevin Quintin,&nbsp;Jean-Marc Simon,&nbsp;Philippe Maingon,&nbsp;Mickaël Andraud,&nbsp;Alexandra Gabro,&nbsp;Julian Jacob,&nbsp;Cyrus Chargari","doi":"10.1016/j.canrad.2025.104670","DOIUrl":"10.1016/j.canrad.2025.104670","url":null,"abstract":"<div><h3>Purpose</h3><div>Palliative radiotherapy aims to relieve cancer-related complications (pain, bleeding, external compression) and improve patients’ quality of life. The 8<!--> <!-->Gy single-fraction regimen is the most commonly used, as it is effective and convenient to patients. Given that the therapeutic effect of palliative radiotherapy may take several weeks to manifest, a 30-day mortality rate below 16 % is considered a quality criteria, since a higher mortality rate would indicate overtreatment of patients who would not benefit from radiotherapy. Our objective was to determine the 30-day mortality rate following single-fraction 8<!--> <!-->Gy palliative radiotherapy in the radiotherapy department of Pitié-Salpêtrière hospital (Paris, France) during the year 2023.</div></div><div><h3>Material and method</h3><div>We conducted a retrospective study including patients treated between January 2nd and December 31st, 2023, regardless of the primary cancer type or the indication for palliative radiotherapy. Mortality was assessed 30 days after radiotherapy. Factors associated with earlier death were analysed using univariate and multivariate analyses, including the following variables: primary cancer type, gender, 3–4 performance status (according to the World Health Organisation), number of systemic treatment lines received, radiotherapy indication, need for hospitalization, and multiple irradiation sites.</div></div><div><h3>Results</h3><div>A total of 125 patients were included in the study. Among them, 18 patients (14.4 %) received two treatments within the year, leading to a total of 143 radiation treatments delivered. Radiotherapy was primarily intended for pain relief in more than 86 % of cases (94 % for bone metastases, 6 % for epiduritis), while haemostatic and decompressive indications accounted for 3 % of cases each. In this cohort, the 30-day mortality rate was 11 %. However, in the subgroup of 11 patients treated with haemostatic intent, the 30-day mortality rate was significantly higher (46 %). A performance status greater than 2 was significantly associated with a higher 30-day mortality rate (odds ratio: 2.6, <em>P</em> <!-->&lt;<!--> <!-->0.01).</div></div><div><h3>Conclusion</h3><div>Our study estimates the 30-day mortality rate at 11 % following single-fraction 8<!--> <!-->Gy palliative radiotherapy among the 125 patients treated for this indication at Pitié-Salpêtrière Hospital in 2023. This study demonstrates the feasibility of using this simple quality criteria as an indicator for internal or external audit evaluations.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 4","pages":"Article 104670"},"PeriodicalIF":1.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144549226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adaptive radiotherapy","authors":"Philippe Maingon,&nbsp;Dr Antoine Mavrikios,&nbsp;Cyrus Chargari","doi":"10.1016/j.canrad.2025.104669","DOIUrl":"10.1016/j.canrad.2025.104669","url":null,"abstract":"","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 4","pages":"Article 104669"},"PeriodicalIF":1.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144570812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prise en charge de la gynécomastie à l’ère des inhibiteurs des récepteurs aux androgènes chez les patients atteints de cancer de la prostate","authors":"Nassim Vibert ,&nbsp;Vérane Achard ,&nbsp;Pierre Pouvreau ,&nbsp;Constance Huck ,&nbsp;Jonathan Khalifa ,&nbsp;Paul Sargos","doi":"10.1016/j.canrad.2025.104665","DOIUrl":"10.1016/j.canrad.2025.104665","url":null,"abstract":"<div><div>This review aims to evaluate the incidence, clinical impact, and available therapeutic options for the management of gynecomastia induced by hormonal therapy, particularly in the era of androgen receptor pathway inhibitors, in patients with prostate cancer. We analysed data from clinical trials evaluating the incidence of gynecomastia under androgen receptor pathway inhibitors and the efficacy of both prophylactic and curative strategies, primarily tamoxifen and male breast radiotherapy, in patients receiving bicalutamide. Androgen receptor pathway inhibitors monotherapy is associated with high rates of gynecomastia (34 to 55 %), whereas combining androgen receptor pathway inhibitors with chemical castration significantly reduces this risk. Prophylactic tamoxifen significantly decreases gynecomastia incidence (down to 10 % versus 73 % without treatment) with good overall tolerance; prophylactic breast radiotherapy also shows efficacy. In the curative setting, tamoxifen appears more effective than radiotherapy, while surgery remains an invasive fallback option. However, extrapolating results obtained with bicalutamide to second-generation androgen receptor pathway inhibitors remains uncertain due to pharmacological and clinical differences. Gynecomastia could become a major complication of androgen receptor pathway inhibitors monotherapy. To date, tamoxifen and prophylactic breast radiotherapy are the most validated strategies, with the former appearing more effective. Further studies are needed to confirm their specific efficacy and safety in patients treated with androgen receptor pathway inhibitors.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 4","pages":"Article 104665"},"PeriodicalIF":1.5,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144365583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Failure patterns analysis of three-dimensional radiotherapy for stage IV non-small cell lung cancer primary tumours","authors":"Wei Zhang,&nbsp;Xin Yu Wu,&nbsp;Jie Liu,&nbsp;Wen Gang Yang,&nbsp;Xia Xia Chen,&nbsp;Bing Lu","doi":"10.1016/j.canrad.2025.104667","DOIUrl":"10.1016/j.canrad.2025.104667","url":null,"abstract":"<div><h3>Purpose</h3><div>The purpose of this study was to investigate the failure patterns of three-dimensional radiotherapy of primary tumours combined with first-line systemic therapy and the influence of radiotherapy-related factors for stage IV non-small cell lung cancer.</div></div><div><h3>Material and methods</h3><div>Seven hundred and forty-eight cases with the initial diagnosis of stage IV non-small cell lung cancer that met the inclusion criteria were selected from 1509 cases registered from March 2003 to July 2021 for univariate analysis and failure patterns test using the chi-square test. Kaplan-Meier survival analysis was performed with the log-rank test and Cox regression model for multifactor prognostic analysis. A value of <em>P</em> below 0.05 indicated a statistically significant difference.</div></div><div><h3>Results</h3><div>The failure incidence of first-line treatment was 72.3 % in 748 cases and 33.6 % within 6<!--> <!-->months, 38.8 % between 6 and 12<!--> <!-->months, 19.4 % between 12 and 24<!--> <!-->months and 8.1 % after 24<!--> <!-->months. A significant difference was observed in the median survival time, which was 7.2, 13.4, 22.2, and 37.6<!--> <!-->months (<em>χ</em>² <!-->=<!--> <!-->324.580, <em>p</em> <!-->&lt;<!--> <!-->0.000), respectively. The incidence of recurrent failure was 20.4 %. A decrease was observed in the recurrence rate with the increasing dose of radiotherapy to the primary tumour, and no significant difference in the incidence of recurrent failure was observed between oligometastatic and non-oligometastatic tumours. The incidence of metastatic failure was 89.4 %, with the order of incidence as follows (from highest to lowest): brain, bone, lung, liver, pleural cavity, distant lymph nodes, adrenal gland, other body parts. The incidence of additional metastases was approximately 50 %, and the progression of synchronous metastases concerned approximately one third of the cases. The metastatic status, time of treatment failure, pathology type, gender, and at least 63<!--> <!-->Gy during the same period of four to six cycles of chemotherapy were independent factors in the prediction of prognosis.</div></div><div><h3>Conclusion</h3><div>The failure patterns of radiotherapy for primary tumours in stage IV non-small cell lung cancer was different from that of first-line systemic therapy alone, with significantly lower local failure, predominant metastatic failure, and the highest incidence of brain metastases. The later treatment failure occurs, the longer will be the oligometastatic status. Oligometastatic cancer, female sex, non-squamous cell carcinoma, the late occurrence of treatment failure, and at least 63<!--> <!-->Gy concurrent four to six cycles of chemotherapy were independent prognostic factors for prolonged survival.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 4","pages":"Article 104667"},"PeriodicalIF":1.5,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144365584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of static and dynamic intensity-modulated radiotherapy for nasopharyngeal carcinoma: Dosimetric and normal tissue complication probability analysis","authors":"Oumaima Mendessi ,&nbsp;Bilel Daoud ,&nbsp;Omar Nouri ,&nbsp;Wafa Mnejja ,&nbsp;Tarek Sahnoun ,&nbsp;Jamel Daoud ,&nbsp;Leila Farhat","doi":"10.1016/j.canrad.2025.104645","DOIUrl":"10.1016/j.canrad.2025.104645","url":null,"abstract":"<div><h3>Purpose</h3><div>With the advancement of radiotherapy techniques for nasopharyngeal carcinoma, it is essential to evaluate the comparative effectiveness of volumetric-modulated arc therapy and intensity-modulated radiotherapy. This study aimed to evaluate the dosimetric and radiobiological differences between the two techniques for the treatment of nasopharyngeal carcinomas.</div></div><div><h3>Materials and methods</h3><div>This retrospective study involved replanning of 125 cases of nasopharyngeal carcinoma using both intensity-modulated radiotherapy and volumetric-modulated arc therapy techniques. Dosimetric evaluation was performed using dose–volume histogram parameters, while radiobiological analysis was conducted using normal tissue complication probability models. Target coverage (dose delivered to 95 % of the high-risk planning target volume), mean dose, and maximum dose to organs at risk, as well as normal tissue complication probability values, were compared between the two techniques.</div></div><div><h3>Results</h3><div>Both intensity-modulated radiotherapy and volumetric-modulated arc therapy provided comparable dosimetric outcomes. Volumetric-modulated arc therapy showed advantages in certain parameters, with a higher dose delivered to 95 % of the high-risk planning target volume and lower maximum dose for the right and left optic nerves, chiasma, and lenses. Conversely, intensity-modulated radiotherapy provided better sparing of the parotid glands, resulting in lower normal tissue complication probability values. The larynx, pharynx, and thyroid also received lower mean doses with intensity-modulated radiotherapy. The results remained consistent in subgroups of both early and advanced stages of nasopharyngeal carcinoma.</div></div><div><h3>Conclusion</h3><div>Intensity-modulated radiotherapy and volumetric-modulated arc therapy both have distinct advantages in treating nasopharyngeal carcinoma. Organs at risk protected vary between the two techniques. The radiobiological parameters, including normal tissue complication probability models and dosimetric measures, highlight the differential benefits of each technique.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 4","pages":"Article 104645"},"PeriodicalIF":1.5,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144365097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First experiences with an adaptive pelvic radiotherapy system: Analysis of treatment times and learning curve","authors":"David Benzaquen ,&nbsp;Daniel Taussky ,&nbsp;Vincent Fave ,&nbsp;Jarno Bouveret ,&nbsp;Farid Lamine ,&nbsp;Gladys Letenneur ,&nbsp;Amandine Halley ,&nbsp;Yusuf Solmaz ,&nbsp;Ambroise Champion","doi":"10.1016/j.canrad.2025.104647","DOIUrl":"10.1016/j.canrad.2025.104647","url":null,"abstract":"<div><h3>Purpose</h3><div>The Varian Ethos system allows not only on-treatment-table plan adaptation but also automated contouring with the aid of artificial intelligence. This study evaluates the initial clinical implementation of an adaptive pelvic radiotherapy system, focusing on the treatment times and the associated learning curve.</div></div><div><h3>Material and methods</h3><div>We analyzed the data from 903 consecutive treatments for most urogenital cancers at our center. The treatment time was calculated from the time of the first cone-beam computed tomography scan used for replanning until the end of treatment. To calculate whether treatments were generally shorter over time, we divided the date of the first treatment into 3-months quartiles. Differences between the groups were calculated using <em>t</em>-tests.</div></div><div><h3>Results</h3><div>The mean time from the first cone-beam computed tomography scan to the end of treatment was 25.9<!--> <!-->min (standard deviation: 6.9<!--> <!-->min). Treatment time depended on the number of planning target volumes and treatment of the pelvic lymph nodes. The mean time from cone-beam computed tomography to the end of treatment was 37 % longer if the pelvic lymph nodes were treated and 26 % longer if there were more than two planning target volumes. There was a learning curve: in linear regression analysis, both quartiles of months of treatment (odds ratio [OR]: 1.3, 95 % confidence interval [CI]: 1.8–0.70, <em>P</em> <!-->&lt;<!--> <!-->0.001) and the number of planning target volumes (OR: 3.0, 95 % CI: 2.6–3.4, <em>P</em> <!-->&lt;<!--> <!-->0.001) were predictive of treatment time.</div></div><div><h3>Conclusion</h3><div>Approximately two-thirds of the treatments were delivered within 33<!--> <!-->min. Treatment time was strongly dependent on the number of separate planning target volumes. There was a continuous learning curve.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 4","pages":"Article 104647"},"PeriodicalIF":1.5,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144298496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Qualitative evaluation of automatic liver segmentation in computed tomography images for clinical use in radiation therapy","authors":"Dorea Maria Khalal ,&nbsp;Souleyman Slimani ,&nbsp;Zine Eddine Bouraoui ,&nbsp;Hacene Azizi","doi":"10.1016/j.canrad.2025.104648","DOIUrl":"10.1016/j.canrad.2025.104648","url":null,"abstract":"<div><h3>Purpose</h3><div>Segmentation of target volumes and organs at risk on computed tomography (CT) images constitutes an important step in the radiotherapy workflow. Artificial intelligence-based methods have significantly improved organ segmentation in medical images. Automatic segmentations are frequently evaluated using geometric metrics. Before a clinical implementation in the radiotherapy workflow, automatic segmentations must also be evaluated by clinicians. The aim of this study was to investigate the correlation between geometric metrics used for segmentation evaluation and the assessment performed by clinicians.</div></div><div><h3>Materials and Methods</h3><div>In this study, we used the U-Net model to segment the liver in CT images from a publicly available dataset. The model's performance was evaluated using two geometric metrics: the Dice similarity coefficient and the Hausdorff distance. Additionally, a qualitative evaluation was performed by clinicians who reviewed the automatic segmentations to rate their clinical acceptability for use in the radiotherapy workflow. The correlation between the geometric metrics and the clinicians’ evaluations was studied.</div></div><div><h3>Results</h3><div>The results showed that while the Dice coefficient and Hausdorff distance are reliable indicators of segmentation accuracy, they do not always align with clinician segmentation. In some cases, segmentations with high Dice scores still required clinician corrections before clinical use in the radiotherapy workflow.</div></div><div><h3>Conclusion</h3><div>This study highlights the need for more comprehensive evaluation metrics beyond geometric measures to assess the clinical acceptability of artificial intelligence-based segmentation. Although the deep learning model provided promising segmentation results, the present study shows that standardized validation methodologies are crucial for ensuring the clinical viability of automatic segmentation systems.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 4","pages":"Article 104648"},"PeriodicalIF":1.5,"publicationDate":"2025-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144279702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First case report of radiation-recall myositis following trabectedin in patient with stage IV mesenchymal chondrosarcoma","authors":"Chiara Casale,&nbsp;Marie-Pierre Sunyach,&nbsp;Salvatore Cozzi,&nbsp;Camille Roukoz","doi":"10.1016/j.canrad.2025.104646","DOIUrl":"10.1016/j.canrad.2025.104646","url":null,"abstract":"<div><div>Radiation recall is a rare phenomenon in which inflammation ensues on a previously irradiated tissue after the administration of a precipitating systemic agent. This reaction may appear anytime between weeks to years after radiotherapy, and it can be caused by a variety of drugs (mainly cytotoxic agents). Skin is the most commonly involved organ and despite the poor insight regarding the pathophysiology of this phenomenon, many case reports have been published on radiation recall dermatitis. In one third of cases, however, radiation recall occurs within internal organs or subcutaneous tissues. Radiation recall myositis is a rare example of this, which has most frequently been reported after the administration of gemcitabine in oncologic patients. We report a case of trabectedin-induced radiation recall myositis occurring 5<!--> <!-->months after stereotactic body radiation therapy on a metastatic muscle lesion in a patient with stage IV mesenchymal chondrosarcoma. To our knowledge, this is the first published case of trabectedin-induced radiation recall myositis.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 4","pages":"Article 104646"},"PeriodicalIF":1.5,"publicationDate":"2025-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144279703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial intelligence for radiotherapy dose prediction: A comprehensive review","authors":"Arezoo Kazemzadeh ,&nbsp;Reza Rasti ,&nbsp;Mohammad Bagher Tavakoli","doi":"10.1016/j.canrad.2025.104630","DOIUrl":"10.1016/j.canrad.2025.104630","url":null,"abstract":"<div><div>Patient outcomes are significantly impacted by the effectiveness and quality of radiation treatment planning. Deep learning, a branch of artificial intelligence, is a potent tool for enhancing and automating dose prediction processes. This article provides a comprehensive and critical analysis of deep learning-based dose prediction methods in radiotherapy, with a focus on convolutional neural networks. A comprehensive search throughout Elsevier Scopus®, Medline, and Web of Science™ literature databases was conducted to locate relevant papers published between 2018 and 2024. The use of deep learning methods for dose prediction is thoroughly examined in this paper. Analysis of these dose prediction approaches provides valuable insights into the potential of this technology to improve radiation treatment planning, particularly in the critical area of automating the dose prediction process. The findings aim to guide future research and facilitate the safe and effective integration of artificial intelligence in clinical workflows.</div></div><div><div>Les résultats des traitements pour les patients sont fortement influencés par l’efficacité et la qualité de la planification du traitement par radiothérapie. L’apprentissage profond, une branche de l’intelligence artificielle, est un outil puissant pour améliorer et automatiser les processus de prédiction des doses. Cet article fournit une analyse complète et critique des méthodes de prédiction des doses basées sur l’apprentissage profond dans le cadre de la radiothérapie, en se concentrant sur les réseaux neuronaux convolutifs. Une recherche approfondie dans les bases de données bibliographiques Elsevier Scopus®, Medline et Web of Science™ a été effectuée pour localiser les articles pertinents publiés entre 2018 et 2024. L’utilisation des méthodes d’apprentissage profond pour la prédiction des doses a été examinée en détail dans cet article. L’analyse de ces approches de prédiction des doses offre des perspectives précieuses sur le potentiel de cette technologie pour améliorer la planification des traitements par irradiation, en particulier dans le domaine critique de l’automatisation du processus de prédiction des doses. Les résultats visent à guider les recherches futures et à faciliter l’intégration sûre et efficace de l’intelligence artificielle dans les flux de travail cliniques.</div></div>","PeriodicalId":9504,"journal":{"name":"Cancer Radiotherapie","volume":"29 4","pages":"Article 104630"},"PeriodicalIF":1.5,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144261911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}